Table 4.
The prevalence of AECA and autoantibodies directed to specific antigens of ANCA
| AECA and ANCA directed to specific antigens other than MPO |
Number and percentage with ANCA specificity |
||
|---|---|---|---|
|
Patients with PTU-induced vasculitis |
Patients with PTU-induced MPO-ANCA but without clinical vasculitis |
P value | |
| (n = 17) | (n = 11) | ||
|
AECA |
15 (88.2%) |
0 (0) |
<0.001 |
|
PR3 |
5 (29.4%) |
1 (9.1%) |
0.380 |
|
HLE |
12 (70.6%) |
3 (27.3%) |
0.011 |
|
Lactoferrin |
14 (82.4%) |
5 (45.5%) |
0.010 |
|
Cathepsin G |
11 (64.7%) |
0 (0) |
<0.001 |
|
BPI |
0 (0) |
1 (9.1%) |
0.209 |
|
Azurocidin |
12 (70.6%) |
1 (9.1%) |
<0.001 |
| Number of ANCA target antigens recognized | 3 (2–4) | 0 (0–2%) | <0.001 |
PR3, Proteinase 3; HLE, human leukocyte elastase; BPI, bactericidal/permeability-increasing protein.